Evidence map›Paper›PMID 40011316›Full record

ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2025

Genotyping and treatment issues with 'unusual' HCV 1 subtypes.

Cinzia Caudai, Piera Pierotti, Barbara Rossetti, Pierluigi Blanc, Maurizio Zazzi

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Cinzia CaudaiMicrobiology and Virology Unit, Siena University Hospital, Viale M. Bracci, 16, 53100, Siena, Italy. cinziacaudai@gmail.com.ORCID http://orcid.org/0000-0003-4509-4891
Piera PierottiInfectious Diseases Unit, S. Maria Annunziata Hospital, Florence, Italy.
Barbara RossettiInfectious Diseases Unit, Siena University Hospital, Siena, Italy.
Pierluigi BlancInfectious Diseases Unit, S. Maria Annunziata Hospital, Florence, Italy.
Maurizio ZazziDepartment of Medical Biotechnologies, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0002-0344-6281

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unusual non 1a/1b HCV 1 subtypes are mostly prevalent in Sub-Saharan Africa. These variants harbour resistance associated substitutions as natural polymorphisms in the NS5A region and are difficult to characterize and treat. We report the HCV genome sequences from two African subjects with unusual subtype 1 g and 1e treated with the pangenotypic regimen sofosbuvir/velpatasvir with failure in the latter. Sequence analysis of different regions of the HCV genome in a subtype 1 reference panel and use of multiple subtyping tools showed that the NS5A region is the most suitable to detect these unusual HCV subtypes and assist treatment choices.

Indexed as

Antiviral AgentsHepacivirusHepatitis CHepatitis C, ChronicCarbamatesDrug CombinationsDrug Resistance, ViralGenome, ViralGenotypeHeterocyclic Compounds, 4 or More RingsHumansRNA-Dependent RNA PolymeraseSofosbuvirViral Nonstructural ProteinsAntiviral AgentsCarbamatesDrug CombinationsHeterocyclic Compounds, 4 or More RingsNS-5 protein, hepatitis C virusRNA-Dependent RNA PolymeraseSofosbuvirsofosbuvir-velpatasvir drug combinationViral Nonstructural ProteinsDirect-acting antiviralsDrug resistanceHCV 1 genotypeHCV genotyping assaysUnusual HCV subtypes

Identifiers

PMID40011316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.